Research focus

Clinical immunology

Biotest has great expertise in the area of therapy with polyvalent immunoglobulins (IVIg) in primary immune deficiencies and autoimmune diseases. Building on this expertise we develop drugs for the treatment of chronic progressive diseases of the immune system.

The projects involve new and further developments in the IVIg area. We are also adding the two monoclonal antibodies Tregalizumab (BT-061) and BT-063 to the existing portfolio of biological medications in immunology. They are being developed in rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus) and for the treatment of other autoimmune diseases.

Biotest has been active for many years in the development and production of hyperimmunoglobulins. These are medications that are used in the treatment of chronic viral infectious diseases such as hepatitis B to prevent reinfection after organ transplantation. A recent Biotest development in this area is Civacir®, a hepatitis C hyperimmunoglobulin for the prevention of reinfection of a hepatitis C virus-induced liver transplant.

Clinical immunology pipeline

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

Tregalizumab
BT-061

other diseases

Tregalizumab

BT-061
other diseases

 

BT-063

Systemic lupus erythematosus

BT-063
Systemic lupus erythematosus

 

Civacir®
Civacir

Prophylaxis hepatitis C reinfection

Civacir®

Civacir
Prophylaxis hepatitis C reinfection

 

Cytotect 70
BT-084

Congenital CMV infection prophylaxis

Cytotect 70

BT-084
Congenital CMV infection prophylaxis